Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Fate Therapeutics (FATE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,246,356
  • Shares Outstanding, K 65,186
  • Annual Sales, $ 4,740 K
  • Annual Income, $ -66,600 K
  • 60-Month Beta 1.69
  • Price/Sales 245.20
  • Price/Cash Flow N/A
  • Price/Book 7.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.32
  • Number of Estimates 6
  • High Estimate -0.18
  • Low Estimate -0.39
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +13.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.55 +22.96%
on 06/12/19
20.65 -7.41%
on 05/29/19
+0.38 (+2.03%)
since 05/17/19
3-Month
15.10 +26.62%
on 04/18/19
20.65 -7.41%
on 05/29/19
+0.41 (+2.19%)
since 03/15/19
52-Week
8.64 +121.30%
on 07/31/18
20.65 -7.41%
on 05/29/19
+7.62 (+66.26%)
since 06/15/18

Most Recent Stories

More News
Fate Therapeutics to Present at the Jefferies 2019 Healthcare Conference

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that...

FATE : 19.12 (+7.24%)
Fate Therapeutics (FATE) Surges: Stock Moves 6.8% Higher

Fate Therapeutics (FATE) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

ACOR : 7.68 (+1.99%)
FATE : 19.12 (+7.24%)
Westleaf Selected for Manitoba Cannabis Store Licence

Opportunity to build retail store and online sales expands distribution footprint

WSLFF : 0.4000 (+31.58%)
GNCA : 5.38 (+2.09%)
EYEG : 0.23 (unch)
FGEN : 43.00 (+5.70%)
FATE : 19.12 (+7.24%)
WL.VN : 0.520 (+25.30%)
Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -30.43% and -10.54%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

FATE : 19.12 (+7.24%)
Fate Therapeutics: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Fate Therapeutics Inc. (FATE) on Tuesday reported a loss of $19.8 million in its first quarter.

FATE : 19.12 (+7.24%)
Fate Therapeutics Reports First Quarter 2019 Financial Results and Highlights Operational Progress

First-ever Patient Treated in U.S. with an iPSC-derived Cell Therapy Successfully Advances through Six-dose Treatment Course

FATE : 19.12 (+7.24%)
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2019 Financial Results

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that...

FATE : 19.12 (+7.24%)
Fate Therapeutics Announces Five Presentations at the American Society of Gene & Cell Therapy 22nd Annual Meeting

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that...

FATE : 19.12 (+7.24%)
Fate Therapeutics Appoints Wayne Chu, M.D. as Vice President, Clinical Development

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that...

FATE : 19.12 (+7.24%)
Investor Expectations to Drive Momentum within Fate Therapeutics, Nuance Communications, DHT, Hess Midstream Partners LP, Hamilton Lane, and Mid-America Apartment Communities -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fate Therapeutics, Inc. (NASDAQ:FATE),...

NUAN : 16.68 (-0.89%)
DHT : 5.57 (+2.39%)
HESM : 19.15 (+0.26%)
HLNE : 54.52 (+2.14%)
FATE : 19.12 (+7.24%)
MAA : 118.81 (+0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

See More Share

Trade FATE with:

Business Summary

Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.

See More

Key Turning Points

2nd Resistance Point 20.23
1st Resistance Point 19.68
Last Price 19.12
1st Support Level 18.17
2nd Support Level 17.21

See More

52-Week High 20.65
Last Price 19.12
Fibonacci 61.8% 16.06
Fibonacci 50% 14.65
Fibonacci 38.2% 13.23
52-Week Low 8.64

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar